Cargando…

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach

OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open‐label extension of the AS Study for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Webers, Casper, Essers, Ivette, van Tubergen, Astrid, Braun, Jürgen, Heldmann, Frank, Baraliakos, Xenofon, Boonen, Annelies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901401/
https://www.ncbi.nlm.nih.gov/pubmed/28575536
http://dx.doi.org/10.1002/acr.23299
_version_ 1783314608494215168
author Webers, Casper
Essers, Ivette
van Tubergen, Astrid
Braun, Jürgen
Heldmann, Frank
Baraliakos, Xenofon
Boonen, Annelies
author_facet Webers, Casper
Essers, Ivette
van Tubergen, Astrid
Braun, Jürgen
Heldmann, Frank
Baraliakos, Xenofon
Boonen, Annelies
author_sort Webers, Casper
collection PubMed
description OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open‐label extension of the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) were used. WTP was included at baseline in EASIC and comprised a hypothetical scenario exploring whether the patient would be willing to pay for beneficial effects of infliximab and, if so, what amount they would be willing to pay per administration. Factors associated with WTP were explored using zero‐inflated negative binomial (ZINB) regressions. RESULTS: Of the 85 patients, 63 (74.1%) were willing to pay, and among these, the mean amount they were willing to pay per administration was €275 (median €100 [interquartile range €50–200]). Multivariable ZINB analysis showed that Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response was associated with a 7‐fold lower likelihood to pay 0 euros (odds ratio [OR] 0.14 [95% confidence interval (95% CI) 0.03–0.71]) and a 3‐fold increase in the amount willing to pay (exp(β) = 3.32 [95% CI 1.44–7.69]). In addition, the country of residence was associated with a lower likelihood to pay 0 euros (OR 0.07 [95% CI 0.02–0.36]), while increased age was associated with the amount willing to pay (exp(β) = 1.05 [95% CI 1.01–1.09]). CONCLUSION: In a hypothetical scenario, three‐quarters of patients with AS receiving long‐term infliximab stated that they were willing to pay an out‐of‐pocket contribution for this treatment. Treatment response contributed to the willingness as well as to the amount patients were willing to pay.
format Online
Article
Text
id pubmed-5901401
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59014012018-04-24 Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach Webers, Casper Essers, Ivette van Tubergen, Astrid Braun, Jürgen Heldmann, Frank Baraliakos, Xenofon Boonen, Annelies Arthritis Care Res (Hoboken) Ankylosing Spondylitis OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open‐label extension of the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) were used. WTP was included at baseline in EASIC and comprised a hypothetical scenario exploring whether the patient would be willing to pay for beneficial effects of infliximab and, if so, what amount they would be willing to pay per administration. Factors associated with WTP were explored using zero‐inflated negative binomial (ZINB) regressions. RESULTS: Of the 85 patients, 63 (74.1%) were willing to pay, and among these, the mean amount they were willing to pay per administration was €275 (median €100 [interquartile range €50–200]). Multivariable ZINB analysis showed that Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response was associated with a 7‐fold lower likelihood to pay 0 euros (odds ratio [OR] 0.14 [95% confidence interval (95% CI) 0.03–0.71]) and a 3‐fold increase in the amount willing to pay (exp(β) = 3.32 [95% CI 1.44–7.69]). In addition, the country of residence was associated with a lower likelihood to pay 0 euros (OR 0.07 [95% CI 0.02–0.36]), while increased age was associated with the amount willing to pay (exp(β) = 1.05 [95% CI 1.01–1.09]). CONCLUSION: In a hypothetical scenario, three‐quarters of patients with AS receiving long‐term infliximab stated that they were willing to pay an out‐of‐pocket contribution for this treatment. Treatment response contributed to the willingness as well as to the amount patients were willing to pay. John Wiley and Sons Inc. 2018-02-18 2018-04 /pmc/articles/PMC5901401/ /pubmed/28575536 http://dx.doi.org/10.1002/acr.23299 Text en © 2017, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Ankylosing Spondylitis
Webers, Casper
Essers, Ivette
van Tubergen, Astrid
Braun, Jürgen
Heldmann, Frank
Baraliakos, Xenofon
Boonen, Annelies
Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
title Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
title_full Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
title_fullStr Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
title_full_unstemmed Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
title_short Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
title_sort valuing treatment with infliximab for ankylosing spondylitis using a willingness‐to‐pay approach
topic Ankylosing Spondylitis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901401/
https://www.ncbi.nlm.nih.gov/pubmed/28575536
http://dx.doi.org/10.1002/acr.23299
work_keys_str_mv AT weberscasper valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach
AT essersivette valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach
AT vantubergenastrid valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach
AT braunjurgen valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach
AT heldmannfrank valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach
AT baraliakosxenofon valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach
AT boonenannelies valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach